GSK Appoints Royal Philips CEO Roy Jakobs as Non-Executive Director Effective July 2026

Roy Jakobs to Join GSK Board as Non-Executive Director

GSK has confirmed that Roy Jakobs will join its Board as a Non-Executive Director starting 13 July 2026. Currently serving as CEO of Royal Philips, a global leader in health technology, Mr Jakobs is expected to contribute valuable insights aligned with GSK's strategic priorities in biopharmaceutical innovation, particularly in patient monitoring and imaging technologies.

This appointment followed a comprehensive selection process led by GSK's Nominations & Corporate Governance Committee, supported by an external search firm. The Board is confident in Mr Jakobs' qualifications and commitment to the role, reinforcing GSK's leadership as it drives innovation and growth.

Professional Background of Roy Jakobs

Since 2022, Roy Jakobs has led Royal Philips, a company with €17.8 billion in sales in 2025 and a global workforce of 65,000. His prior senior roles at Shell and Elsevier, combined with an MBA, equip him with broad leadership experience. His expertise in managing a major health technology firm will support GSK's integration of innovative technologies into its biopharmaceutical operations.

Mr Jakobs' appointment is anticipated to bring fresh perspectives that align with GSK's mission to develop better medicines and enhance shareholder value.

Strategic Significance for GSK

Adding Roy Jakobs to the Board is a strategic move to incorporate health technology expertise into GSK’s governance. As GSK aims to accelerate growth and deliver innovative treatments, Mr Jakobs’ experience in adjacent health technologies is expected to play a pivotal role in expanding product offerings and improving patient outcomes.

Investors should monitor how this appointment influences GSK’s strategic direction and technology integration within its biopharmaceutical initiatives. Although no immediate share price impact has been reported, the long-term implications for GSK’s growth trajectory could be substantial.

Compensation and Governance Information

Roy Jakobs will receive an annual fee of £122,258 as a Non-Executive Director. He will also work towards fulfilling GSK’s share ownership requirement, which mandates holding shares equivalent to twice the standard annual fee, in accordance with the company’s shareholder-approved remuneration policy.

The Board has classified Mr Jakobs as an independent Non-Executive Director under the UK Corporate Governance Code. His appointment is governed by a letter of appointment rather than a service contract, available upon request from GSK’s Company Secretary. There are no further disclosures required under Listing Rule 6.4.8R.

Current Composition of GSK’s Board

With Roy Jakobs joining, GSK’s Board consists of a diverse leadership team, including Non-Executive Chair Sir Jonathan Symonds, CEO Luke Miels, and CFO Julie Brown. This blend of executive and independent directors supports effective governance and strategic oversight as GSK pursues its growth and innovation objectives.

The Board’s composition reflects GSK’s dedication to strong governance practices and accountability in steering the company’s biopharmaceutical advancements.

GSK’s Commitment to Growth and Innovation

GSK is a global biopharmaceutical company focused on combining science, technology, and talent to advance disease prevention and treatment. The company prioritizes accelerating growth and delivering innovative medicines to meet patient needs and maximize shareholder value. Roy Jakobs’ appointment complements these goals by adding health technology expertise to the Board.

As GSK navigates the complexities of the biopharmaceutical landscape, the leadership and insights of experienced directors like Mr Jakobs will be vital in driving innovation and enhancing company performance.

Investor Outlook and Considerations

Investors will be closely observing how Roy Jakobs’ expertise influences GSK’s strategic initiatives and operational performance. His background in health technology may unlock new opportunities for product development and improved patient outcomes. GSK’s focus on growth and innovation remains a key factor for future success.

While immediate effects on GSK’s share price are not evident, the long-term benefits of Mr Jakobs’ leadership could significantly impact the company’s growth prospects. Investors should track GSK’s progress in integrating health technology and achieving its strategic targets.